• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

Jazz Pharma Expands Into CBD Market With Planned Acquisition

February 12, 2021 by admin

Jazz Pharmaceuticals and GW Pharmaceuticals have entered into a definitive agreement for Jazz to acquire GW for  $7.2 billion. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.

According to a Jazz press release, the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio. GW is a developer and manufacturer of novel, regulatory approved therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases. 

The company’s lead product, Epidiolex® (cannabidiol or CBD) oral solution is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC)—all of which are rare diseases characterized by severe early-onset epilepsy. Epidiolex was the first plant-derived cannabinoid medicine ever approved by the U.S. Food and Drug Administration (FDA). 

Beyond Epidiolex, GW has a scientific platform and innovative pipeline of CBD product candidates, as well as specialized manufacturing expertise, developed over two decades of cannabinoid science. This pipeline includes nabiximols, for which the company is in Phase 3 trials to seek FDA approval for treatment of spasticity associated with multiple sclerosis and spinal cord injury.

“Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business,” said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. “We are excited to add GW’s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue, and drive sustainable, long-term value creation opportunities.” 

Filed Under: Blog

Primary Sidebar

More to See

Xywav Oral Solution for Idiopathic Hypersomnia

February 16, 2022 By Alan Hickey

New Insomnia Drug Improves Sleep Outcomes for Adults

February 10, 2022 By Alan Hickey

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep industry Sleepiness sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • Sleep Hygiene: Which Bedroom Colors to Avoid and which Promote Good Sleep??
  • Xywav Oral Solution for Idiopathic Hypersomnia
  • New Insomnia Drug Improves Sleep Outcomes for Adults
  • Mark Cuban Billionaire Entrepreneur and Television Personality Launches Online Pharmacy for Generic Drugs
  • Americans Say They’re Sleep-Deprived After the Super Bowl

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2022 · Sleep Diagnosis and Therapy